Nothing Special   »   [go: up one dir, main page]

HK1251219A1 - 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物 - Google Patents

用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物

Info

Publication number
HK1251219A1
HK1251219A1 HK18110501.1A HK18110501A HK1251219A1 HK 1251219 A1 HK1251219 A1 HK 1251219A1 HK 18110501 A HK18110501 A HK 18110501A HK 1251219 A1 HK1251219 A1 HK 1251219A1
Authority
HK
Hong Kong
Prior art keywords
phthalazin
dihydropyrido
prophylaxis
hepatitis
ones
Prior art date
Application number
HK18110501.1A
Other languages
English (en)
Inventor
Zhanling Cheng
Xingchun Han
Yongguang Wang
Song Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1251219A1 publication Critical patent/HK1251219A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18110501.1A 2015-07-28 2018-08-15 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物 HK1251219A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015085265 2015-07-28
PCT/EP2016/067609 WO2017017043A1 (en) 2015-07-28 2016-07-25 Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection

Publications (1)

Publication Number Publication Date
HK1251219A1 true HK1251219A1 (zh) 2019-01-25

Family

ID=56511579

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110501.1A HK1251219A1 (zh) 2015-07-28 2018-08-15 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物

Country Status (6)

Country Link
US (1) US10150740B2 (zh)
EP (1) EP3328858B1 (zh)
JP (1) JP6559324B2 (zh)
CN (1) CN107835813B (zh)
HK (1) HK1251219A1 (zh)
WO (1) WO2017017043A1 (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
BR102017010009A2 (pt) * 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
AU2017277664A1 (en) 2016-06-10 2019-01-24 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN109715624B (zh) 2016-07-29 2022-08-16 广州麓鹏制药有限公司 用于治疗hbv感染的新颖治疗剂
BR112019007450A2 (pt) 2016-10-14 2020-07-07 Precision Biosciences, Inc. meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
KR102522060B1 (ko) 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
DK3590942T3 (da) 2017-03-09 2021-09-06 Fujian Cosunter Pharmaceutical Co Ltd Hepatitis B-virusoverfladeantigeninhibitor
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
EP3675637A4 (en) 2017-08-28 2021-05-19 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
GB201720163D0 (en) * 2017-12-04 2018-01-17 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
TW201927789A (zh) 2017-12-06 2019-07-16 美商因那塔製藥公司 B型肝炎抗病毒試劑
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
TW202416959A (zh) 2018-07-27 2024-05-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯𠯤，其類似物及使用其之方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020043080A1 (en) * 2018-08-28 2020-03-05 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN110950860B (zh) * 2018-09-26 2023-03-31 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
BR112021009854A2 (pt) 2018-11-21 2021-08-17 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
IL290999B1 (en) 2019-09-30 2024-10-01 Gilead Sciences Inc HBV vaccines and HBV treatment methods
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639B2 (en) 2021-06-23 2024-11-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60197684A (ja) 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔ａ〕キノリジン誘導体およびその塩
EA201691261A1 (ru) * 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
BR102017010009A2 (pt) * 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection

Also Published As

Publication number Publication date
WO2017017043A1 (en) 2017-02-02
US10150740B2 (en) 2018-12-11
CN107835813A (zh) 2018-03-23
EP3328858A1 (en) 2018-06-06
EP3328858B1 (en) 2019-05-15
CN107835813B (zh) 2020-04-24
JP6559324B2 (ja) 2019-08-14
US20180127381A1 (en) 2018-05-10
JP2018522897A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
HK1251219A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HK1251221A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的三環4-吡啶酮-3-甲酸衍生物
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
HK1251220A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的四環4-氧代-吡啶-3-甲酸衍生物
IL257384A (en) Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus
HK1219480A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的 -橋連的雜芳基二氫嘧啶
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
IL280769B1 (en) Novel sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
EP3474863A4 (en) PHOSPHORAMIDATE FOR TREATING THE HEPATITIS C VIRUS
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
HK1250480A1 (zh) 用於治療hbv感染的組合物和方法
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
HUE054191T2 (hu) A hepatitis delta vírusfertõzés kezelése
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection